Dive in

We have our own point of view on the people, technologies, and conversations that will shape the future.

Tag results
Life Sciences
Clear all
List view Grid view
Filters

Key Takeaways from J.P. Morgan’s 41st Annual Healthcare Conference​

For those in healthcare, JPM provides the unofficial kickoff to every new year with a chance to recap the year before and inform our view on the year ahead.

Our Investment in Vilya: AI-Enabled Development of a New Class of Medicines
Opportunities and Challenges of Applying Generative AI to Designing New Drugs
Video: Engineering New Drugs With Generative AI at Genesis Therapeutics
Video: Early Cancer Detection With Delfi
Video: Reengineering Drug Discovery With Recursion

Fighting Cancer Through Early Detection and New Therapies: Menlo’s Investments in Delfi and Opna

Cancer remains one of the leading causes of death in the U.S. and worldwide.

Announcing the Digital Health Founder’s Fellowship

Attention Digital Health Founders: We are now accepting applications to attend the Digital Health Founder’s Fellowship

Our Investment In Qualio: A New Breed of Quality Management System for Life Sciences
Life Science Is Being Transformed by Vertical SaaS
The 5 Ps of Therapeutics Investing at Menlo
We Are Hiring a Principal with Therapeutics Expertise: Building a Biotech Franchise at Menlo

Pliant and the 5 Ps of Therapeutics Investing at Menlo

Congratulations to Bernard Coulie and the team at Pliant Therapeutics on a successful IPO!

Investing in H1: SaaS Healthcare Analytics
Bringing Transparency to Healthcare Transactions: Menlo Ventures Invests in Rivet
Investing in Benchling: Software Accelerating Life Science Innovation
Key Takeaways from J.P. Morgan’s 41st Annual Healthcare Conference​

For those in healthcare, JPM provides the unofficial kickoff to every new year with a chance to recap the year before and inform our view on the year ahead.

February 13, 2024Greg Yap, Johnny Hu and Ph.D.
Our Investment in Vilya: AI-Enabled Development of a New Class of Medicines

Predictive and generative AI are entering many new applications. At Menlo Ventures, we are especially excited about applications for AI in drug discovery and development, specifically when new technology can directly address a major unmet need.

September 15, 2023Johnny Hu, Ph.D. and Greg Yap
Opportunities and Challenges of Applying Generative AI to Designing New Drugs

Drug design is both a natural fit and a unique challenge for generative AI, given large but messy datasets, time and cost of real-world testing, and the complexity of human trials.

August 9, 2023Johnny Hu and Ph.D.
Video: Engineering New Drugs With Generative AI at Genesis Therapeutics

Genesis Therapeutics is pioneering AI technologies to create medicines for patients with severe and unmet medical needs.

May 2, 2023Greg Yap
Video: Early Cancer Detection With Delfi

Delfi Diagnostics has developed a test that combines ultra-low-cost sequencing and machine learning to detect cancer early.

March 9, 2023Greg Yap
Video: Reengineering Drug Discovery With Recursion

Recursion is a breakthrough drug discovery company that combines a novel computer vision platform with deep disease biology and chemistry.

March 9, 2023Greg Yap, Johnny Hu and Ph.D.
Fighting Cancer Through Early Detection and New Therapies: Menlo’s Investments in Delfi and Opna

Cancer remains one of the leading causes of death in the U.S. and worldwide.

January 11, 2023Johnny Hu and Ph.D.
Announcing the Digital Health Founder’s Fellowship

Attention Digital Health Founders: We are now accepting applications to attend the Digital Health Founder’s Fellowship

December 6, 2022Greg Yap
Our Investment In Qualio: A New Breed of Quality Management System for Life Sciences

Across life sciences, a quality management system (QMS) is critical for both regulatory compliance and continuous product innovation.

May 25, 2021JP Sanday
Life Science Is Being Transformed by Vertical SaaS

We believe purpose-built vertical SaaS will help make drug discovery more effective and efficient and ultimately improve healthcare outcomes.

April 14, 2021Matt Murphy, JP Sanday and Greg Yap
The 5 Ps of Therapeutics Investing at Menlo

At Menlo, we believe the pace of innovation in new medicines will continue to accelerate, powered by the combination of advances in biology, advances in information technology, and even the lasting implications of the global pandemic.

March 31, 2021Greg Yap
We Are Hiring a Principal with Therapeutics Expertise: Building a Biotech Franchise at Menlo

Here at Menlo, we are building an investing practice focused on three of the most exciting areas of healthcare: therapeutic platforms, digital health, and transformative technologies.

March 23, 2021Greg Yap
Pliant and the 5 Ps of Therapeutics Investing at Menlo

Congratulations to Bernard Coulie and the team at Pliant Therapeutics on a successful IPO!

June 3, 2020Greg Yap
Investing in H1: SaaS Healthcare Analytics

How can we take a critical process and make it better? Many successful companies are built from answering this question.

April 22, 2020Greg Yap
Bringing Transparency to Healthcare Transactions: Menlo Ventures Invests in Rivet

When you rent an apartment, buy a car, pay for education, you know exactly what you are going to pay. Why then, when you go to a doctor or pay for healthcare, do you not know what you will owe?

March 10, 2020Croom Beatty
Investing in Benchling: Software Accelerating Life Science Innovation

It’s rare to meet an entrepreneur who demonstrates both an incredible command of their business and such a clear vision of the magnitude of the opportunity.

July 24, 2019Matt Murphy
loader.svg